Can nuclear magnetic resonance (NMR) spectroscopy reveal different metabolic signatures for lung tumours?

Virchows Archiv

Volumn 457, Issue 6, 2010, Pages 715-725

  Duarte, Iola F ^a,d   Rocha, Cláudia M ^a   Barros, António S ^a   Gil, Ana M ^a   Goodfellow, Brian J ^a,d   Carreira, Isabel M ^b,d   Bernardo, João ^c,d   Gomes, Ana ^c,d   Sousa, Vitor ^c,d   Carvalho, Lina ^c,d  

^a UNIVERSITY OF AVEIRO   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

HRMAS; Lung tumour; Metabolic profile; Multivariate statistics; NMR spectroscopy

Indexed keywords

ACETIC ACID; GLUCOSE; GLUTATHIONE; GLYCEROPHOSPHORYLCHOLINE; GLYCINE; INOSITOL; LACTIC ACID; LYSINE; METHIONINE; PHOSPHOETHANOLAMINE; PHOSPHORYLCHOLINE; TAURINE; URIDINE DIPHOSPHATE;

ADULT; AGED; ARTICLE; CARCINOID; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG PARENCHYMA; LUNG SQUAMOUS CELL CARCINOMA; LUNG TUMOR; MALE; PARTIAL LEAST SQUARES REGRESSION; PLASMA CELL GRANULOMA; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; BIOLOGICAL MARKERS; CARCINOID TUMOR; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLUCOSE; HUMANS; LACTATES; LUNG NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 78651293507     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-010-0993-6     Document Type: Article

References (36)

1. Griffin JL, Shockor JP (2004) Metabolic profiles of cancer cells. Nat Rev Cancer 4:551-561
2. Spratlin JL, Serkova NJ, Eckhardt SG (2009) Clinical applications of metabonomics in oncology: a review. Clin Cancer Res 15:431-440
3. Merz AL, Serkova NJ (2009) Use of nuclear magnetic resonancebased metabonomics in detecting drug resistance in cancer. Biomark Med 3:289-306
4. Sitter B, Bathen TF, Tessem M-B, Gribbestad IS (2009) Highresolution magic angle spinning (HR MAS) MR spectroscopy in metabolic characterization of human cancer. Prog Nucl Magn Reson Spectrosc 54:239-254
5. Hanaoka H, Yoshioka Y, Ito I, Niitu K, Yasuda N (1993) In vitro characterization of lung cancers by the use of 1H nuclear magnetic resonance spectroscopy of tissue extracts and discriminant factor analysis. Magn Reson Med 29:436-440
6. Guo JF, Higashi K, Yokota H, Nagao Y, Ueda Y, Kodama Y, Oguchi M, Taki S, Tonami H, Yamamoto I (2004) In vitro proton magnetic resonance spectroscopic lactate and choline measurements, 18F-FDG uptake, and prognosis in patients with lung adenocarcinoma. J Nucl Med 45:1334-1339
7. 1HMRS as prognostic parameters in patients with non-small-cell lung cancer. J Magn Reson Imaging 25:992-999
8. Fan TW-M, Lane AN, Higashi RM, Bousamra M, Kloecker G, Miller DM (2009) Metabolic profiling identifies lung tumour responsiveness to erlotinib. Exp Mol Pathol 87:83-86
9. Fan TW-M, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, Miller DM (2009) Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM). Mol Cancer 8:41
10. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J (2003) Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med 50:944-954
11. 1H MR spectra. Int J Mol Med 18:859-869
12. Mountford C, Lean C, Malycha P, Russell P (2006) Proton spectroscopy provides accurate pathology on biopsy and in vivo. J Magn Reson Imaging 24:459-477
13. Thomas MA, Lipnick S, Velan SS, Liu X, Banakar S, Binesh N, Ramadan S, Ambrosio A, Raylman RR, Sayre J, DeBruhl N, Bassett L (2009) Investigation of breast cancer using twodimensional MRS. NMR Biomed 22:77-91
14. 1H HR-MAS for childhood brain tumours. NMR Biomed 22:213-219
15. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS (2006) Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 19:30-40
16. Bathen TF, Jensen LR, Sitter B, Fjosne HE, Halgunset J, Axelson DE, Gribbestad IS, Lundgren S (2007) MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat 104:181-189
17. Erb G, Elbayed K, Piotto M, Raya J, Neuville A, Mohr M, Maitrot D, Kehrli P, Namer IJ (2008) Toward improved grading of malignancy in oligodendrogliomas using metabolomics. Magn Reson Med 59:959-965
18. Monleon D, Morales JM, Gonzalez-Darder J, Talamantes F, Cortes O, Gil-Benso R, Lopez-Gines C, Cerda-Nicolas M, Celda B (2008) Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. J Proteome Res 7:2882-2888
19. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, Wu C-L (2005) Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 65:3030-3034
20. 1H HRMAS spectroscopy of biopsy tissues. Magn Reson Med 60:510-516
21. van Asten JJA, Cuijpers V, Hulsbergen-van de Kaa C, Soede-Huijbregts C, Witjes JA, Verhofstad A, Heerschap A (2008) High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies. Magma 21:435-442
22. Sitter B, Bathen TF, Hagen B, Arentz C, Skjeldestad FE, Gribbestad IS (2004) Cervical cancer tissue characterized by high-resolution magic angle spinning MR spectroscopy. Magma 16:174-181
23. Mahon MM, deSouza NM, Dina R, Soutter WP, McIndoe GA, Williams AD, Co IJ (2004) Preinvasive and invasive cervical cancer: an ex vivo proton magic angle spinning magnetic resonance spectroscopy study. NMR Biomed 17:144-153 (Pubitemid 38684563)
24. 31 P magic angle spinning MRS of intact tissue. NMR Biomed 22:191-198
25. Chan ECY, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, Cavill R, Nicholson JK, Keun HC (2009) Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 8:352-361
26. Piotto M, Moussallieh F-M, Dillmann B, Imperiale A, Neuville A, Brigand C, Bellocq J-P, Elbayed K, Namer IJ (2009) Metabolic characterization of primary human colorectal cancers using high resolution magic angle spinning 1H magnetic resonance spectroscopy. Metabolomics 5:292-301
27. Yang Y, Li C, Nie X, Feng X, Chen W, Yue Y, Tang H, Deng F (2007) Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res 6:2605-2614
28. 1H magic angle spinning (MAS) NMR spectra. NMR Biomed 13:64-71
29. Righi V, Mucci A, Schenetti L, Tosi MR, Grigioni WF, Corti B, Bertaccini A, Franceschelli A, Sanguedolce F, Schiavina R, Martorana G, Tugnoli V (2007) Ex vivo HR-MAS magnetic resonance spectroscopy of normal and malignant human renal tissues. Anticancer Res 27:3195-3204
30. Tugnoli V, Mucci A, Schenetti L, Righi V, Calabrese C, Fabbri A, Di Febo G, Tosi MR (2006) Ex vivo HR-MAS magnetic resonance spectroscopy of human gastric adenocarcinomas: a comparison with healthy gastric mucosa. Oncol Rep 16:543-553
31. Jordan KW, Adkins CB, Su L, Halpern EF, Mark EJ, Christiani DC, Cheng LL (2009) Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue-serum pairs. Lung Cancer 68:44-50
32. 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res 9:319-332
33. Travis WD, Brambilla E, Müller-Hermelink HK, Harris C (2004) World Health Organization Classification of Tumours: tumours of the lung, pleura, thymus and heart. IARC Press, Lyon
34. Xu Q-S, Liang Y-Z (2001) Monte Carlo cross validation. Chemometr Intell Lab Syst 56:1-11
35. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM (2006) Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm 3:496-506 (Pubitemid 44639126)
36. Balendiran GK, Dabur R, Fraser D (2004) The role of glutathione in cancer. Cell Biochem Funct 22:343-352